Faes Farma Future Growth
Future criteria checks 0/6
Faes Farma's earnings are forecast to decline at 1.4% per annum while its annual revenue is expected to grow at 1.5% per year. EPS is expected to decline by 1.5% per annum. Return on equity is forecast to be 11.2% in 3 years.
Key information
-1.4%
Earnings growth rate
-1.5%
EPS growth rate
Pharmaceuticals earnings growth | 25.7% |
Revenue growth rate | 1.5% |
Future return on equity | 11.2% |
Analyst coverage | Low |
Last updated | 21 Nov 2024 |
Recent future growth updates
Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 03Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year
Jul 31Recent updates
Faes Farma's (BME:FAE) Dividend Will Be €0.0332
Dec 03Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 03Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316
Dec 18Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316
Dec 04Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?
Nov 24Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly
May 03Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?
Sep 21Is Faes Farma (BME:FAE) A Risky Investment?
Aug 03Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth
Jun 17Is Faes Farma (BME:FAE) Using Too Much Debt?
Mar 27Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14
Dec 13Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17
Nov 29Is Faes Farma (BME:FAE) A Risky Investment?
Sep 21Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year
Jul 31Is Faes Farma (BME:FAE) Using Too Much Debt?
May 01Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)
Apr 07Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?
Mar 22Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations
Mar 06Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment
Feb 22I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease
Jan 16Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly
Dec 08Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 509 | 92 | 93 | N/A | 3 |
12/31/2025 | 499 | 94 | 82 | N/A | 3 |
12/31/2024 | 484 | 90 | 61 | N/A | 3 |
9/30/2024 | 504 | 98 | N/A | N/A | N/A |
6/30/2024 | 494 | 97 | 44 | 106 | N/A |
3/31/2024 | 482 | 95 | N/A | N/A | N/A |
12/31/2023 | 473 | 92 | -1 | 101 | N/A |
9/30/2023 | 472 | 90 | N/A | N/A | N/A |
6/30/2023 | 469 | 90 | -9 | 98 | N/A |
3/31/2023 | 467 | 91 | N/A | N/A | N/A |
12/31/2022 | 462 | 89 | 26 | 107 | N/A |
9/30/2022 | 460 | 86 | N/A | N/A | N/A |
6/30/2022 | 466 | 88 | 50 | 113 | N/A |
3/31/2022 | 449 | 88 | N/A | N/A | N/A |
12/31/2021 | 429 | 82 | 20 | 80 | N/A |
9/30/2021 | 416 | 81 | N/A | N/A | N/A |
6/30/2021 | 398 | 74 | 8 | 56 | N/A |
3/31/2021 | 394 | 73 | N/A | N/A | N/A |
12/31/2020 | 411 | 73 | 53 | 78 | N/A |
9/30/2020 | 408 | 77 | N/A | N/A | N/A |
6/30/2020 | 407 | 73 | 57 | 78 | N/A |
3/31/2020 | 409 | 68 | N/A | N/A | N/A |
12/31/2019 | 383 | 64 | 46 | 68 | N/A |
9/30/2019 | 379 | 60 | N/A | N/A | N/A |
6/30/2019 | 363 | 59 | 51 | 74 | N/A |
3/31/2019 | 351 | 54 | N/A | N/A | N/A |
12/31/2018 | 340 | 52 | 40 | 59 | N/A |
9/30/2018 | 334 | 51 | N/A | N/A | N/A |
6/30/2018 | 330 | 49 | N/A | 58 | N/A |
3/31/2018 | 308 | 47 | N/A | N/A | N/A |
12/31/2017 | 282 | 41 | N/A | 42 | N/A |
9/30/2017 | 266 | 39 | N/A | N/A | N/A |
6/30/2017 | 250 | 39 | N/A | 43 | N/A |
3/31/2017 | 241 | 38 | N/A | N/A | N/A |
12/31/2016 | 237 | 37 | N/A | 50 | N/A |
9/30/2016 | 226 | 35 | N/A | N/A | N/A |
6/30/2016 | 222 | 34 | N/A | 40 | N/A |
3/31/2016 | 220 | 32 | N/A | N/A | N/A |
12/31/2015 | 214 | 30 | N/A | 41 | N/A |
9/30/2015 | 207 | 28 | N/A | N/A | N/A |
6/30/2015 | 203 | 27 | N/A | 42 | N/A |
3/31/2015 | 196 | 26 | N/A | N/A | N/A |
12/31/2014 | 198 | 25 | N/A | 32 | N/A |
9/30/2014 | 195 | 23 | N/A | N/A | N/A |
6/30/2014 | 194 | 24 | N/A | 20 | N/A |
3/31/2014 | 192 | 20 | N/A | N/A | N/A |
12/31/2013 | 193 | 23 | N/A | 32 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FAE's earnings are forecast to decline over the next 3 years (-1.4% per year).
Earnings vs Market: FAE's earnings are forecast to decline over the next 3 years (-1.4% per year).
High Growth Earnings: FAE's earnings are forecast to decline over the next 3 years.
Revenue vs Market: FAE's revenue (1.5% per year) is forecast to grow slower than the Spanish market (5% per year).
High Growth Revenue: FAE's revenue (1.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: FAE's Return on Equity is forecast to be low in 3 years time (11.2%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 08:41 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Faes Farma, S.A. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Álvaro Arístegui Echevarría | Ahorro Corporación |
Kamla Singh | AlphaValue |
Guilherme Sampaio | Banco BPI, S.A. |